HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antonella D'Arminio Monforte Selected Research

Acquired Immunodeficiency Syndrome (AIDS)

11/2020Beyond Italian guidelines in the management of HIV-positive patient.
12/2016Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy.
6/2014Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC).
5/2013Free light chains and the risk of nonmalignant AIDS events in HIV-infected patients treated with combination antiretroviral therapy.
12/2012Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics.
11/2011Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study.
1/2010Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy.
1/2008Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART.
5/2007Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies.
12/2003Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome-related Kaposi sarcoma.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Antonella D'Arminio Monforte Research Topics

Disease

13Acquired Immunodeficiency Syndrome (AIDS)
11/2020 - 01/2002
10Infections
03/2024 - 10/2002
6Disease Progression
10/2023 - 01/2002
6Coinfection
12/2022 - 10/2002
5COVID-19
02/2024 - 11/2020
3Fibrosis (Cirrhosis)
12/2022 - 06/2011
3Myocardial Infarction
07/2011 - 04/2008
2Pneumonia (Pneumonitis)
10/2023 - 03/2023
2Chronic Renal Insufficiency
12/2022 - 10/2019
2Hepatitis C
12/2022 - 06/2014
2Liver Cirrhosis (Hepatic Cirrhosis)
01/2022 - 09/2014
2Inflammation (Inflammations)
06/2021 - 06/2021
2Viremia
01/2017 - 08/2003
2HIV Infections (HIV Infection)
01/2017 - 05/2012
2Cardiovascular Diseases (Cardiovascular Disease)
09/2013 - 07/2011
2Kaposi Sarcoma (Kaposi's Sarcoma)
12/2003 - 08/2003
1Respiratory Insufficiency (Respiratory Failure)
10/2023
1Fever (Fevers)
12/2022
1Cytokine Release Syndrome
12/2022
1Dyspnea (Shortness of Breath)
12/2022
1Liver Diseases (Liver Disease)
01/2022
1Chronic Hepatitis C
01/2022
1Cognitive Dysfunction
11/2021
1Headache (Headaches)
11/2021
1Confusion (Bewilderment)
11/2021
1Overweight
06/2021
1Hyperphosphatemia
11/2019
1Stroke (Strokes)
08/2019
1Lymphopenia (Lymphocytopenia)
06/2010
1Metabolic Syndrome (Dysmetabolic Syndrome X)
01/2010
1Diabetes Mellitus
01/2010
1Coronary Disease (Coronary Heart Disease)
04/2008
1Osteoporosis
08/2006
1Neoplasms (Cancer)
08/2003

Drug/Important Bio-Agent (IBA)

9RNA (Ribonucleic Acid)IBA
12/2022 - 01/2008
5Biomarkers (Surrogate Marker)IBA
12/2022 - 01/2008
3Anti-HIV Agents (AIDS Drugs)IBA
10/2019 - 01/2010
2Antiviral Agents (Antivirals)IBA
12/2022 - 01/2022
2C-Reactive ProteinIBA
06/2021 - 09/2013
2Protease Inhibitors (Protease Inhibitor)IBA
10/2019 - 01/2010
2HDL CholesterolIBA
09/2014 - 07/2011
2Hepatitis B Surface Antigens (HBsAg)FDA Link
01/2013 - 01/2010
2abacavir (Ziagen)FDA Link
11/2011 - 04/2008
2Reverse Transcriptase InhibitorsIBA
04/2008 - 08/2006
2NucleosidesIBA
04/2008 - 08/2006
1DNA (Deoxyribonucleic Acid)IBA
03/2024
1reparixinIBA
10/2023
1Interleukin-8 (Interleukin 8)IBA
10/2023
1sarilumabIBA
03/2023
1Interleukin-6 InhibitorsIBA
03/2023
1Growth Differentiation Factor 15IBA
12/2022
1Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
01/2022
1Oxygen (Dioxygen)IBA
11/2020
1remdesivirIBA
11/2020
1IronIBA
11/2019
1Phosphates (Orthophosphate)IBA
11/2019
1Ribavirin (Virazole)FDA LinkGeneric
01/2018
1Tenofovir (Viread)FDA Link
01/2018
1Integrase InhibitorsIBA
01/2018
1Viral RNAIBA
01/2018
1LDL CholesterolIBA
09/2014
1Alkaline PhosphataseIBA
09/2014
1Glucose (Dextrose)FDA LinkGeneric
09/2014
1HDL LipoproteinsIBA
09/2014
1LDL Lipoproteins (beta Lipoproteins)IBA
09/2014
1EnzymesIBA
06/2014
1LopinavirFDA Link
11/2011
1efavirenz (Sustiva)FDA Link
11/2011
1Triglycerides (Triacylglycerol)IBA
07/2011
1CholesterolIBA
07/2011
1Atazanavir Sulfate (Reyataz)FDA Link
06/2011
1Antihypertensive Agents (Antihypertensives)IBA
01/2010
1LipidsIBA
01/2010
1ThymidineIBA
01/2010
1Zidovudine (Retrovir)FDA LinkGeneric
04/2008
1Lamivudine (Epivir)FDA Link
04/2008
1Stavudine (Zerit)FDA LinkGeneric
04/2008
1Didanosine (Videx)FDA LinkGeneric
04/2008
1Indicators and Reagents (Reagents)IBA
01/2008
1insulin receptor-related receptor (IRR)IBA
01/2008
1Amphotericin B (Amphotericin)FDA LinkGeneric
01/2008
1AzolesIBA
01/2008
1Hemoglobins (Hemoglobin)IBA
01/2002

Therapy/Procedure

12Highly Active Antiretroviral Therapy (HAART)
06/2021 - 01/2002
11Therapeutics
10/2023 - 10/2002
1Retention in Care
02/2024
1Aftercare (After-Treatment)
12/2022
1Art Therapy
01/2017